logo

Calliditas Therapeutics Ab (Publ) (CALT)



Trade CALT now with
  Date
  Headline
12/20/2022 10:22:28 PM Calliditas CEO Renée Aguiar-Lucander Purchases 50,000 Shares Through Calliditas' Warrant Program 2019/2022
12/13/2022 3:04:10 AM Calliditas Enters License Deal With Viatris To Commercialize Specialty Therapy For IgA Nephropathy In Japan
11/15/2022 2:45:29 AM Calliditas' Partner Everest Medicine's NDA For Nefecon Accepted By China NMPA
8/18/2022 1:25:59 AM Calliditas Therapeutics Q2 Net Sales SEK 64.0 Mln; Operating Loss SEK 209.8 Mln
7/11/2022 6:58:26 AM Calliditas Adds Head Of Human Resources Sandra Frithiof And Group General Counsel Jonathan Schur To Management Team
5/19/2022 8:46:19 AM Calliditas Therapeutics's Kinpeygo Receives Positive CHMP Opinion In IgA Nephropathy
5/18/2022 1:33:32 AM Calliditas Therapeutics Reports Q1 Net Sales Of SEK 49.7 Mln; Loss/shr Of SEK 2.62
3/13/2022 9:12:26 PM Everest Medicines Reaches Deal With Calliditas , Expanding Territory License To Commercialize NEFECON In South Korea
2/15/2022 4:47:43 AM Calliditas Therapeutics Says First Patient Randomized In Pivotal TRANSFORM Study With Setanaxib
1/28/2022 2:17:36 AM Calliditas Therapeutics Announces Commercial Availability And Initial Sales Of TARPEYO
11/18/2021 1:25:29 AM Calliditas Therapeutics Q3 Operating Profit SEK 7.9 Mln Vs. Operating Loss SEK 104.9 Mln Prior Year